Tags

Type your tag names separated by a space and hit enter

BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants.
Nature. 2021 08; 596(7871):273-275.Nat

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents1-5. Here we show that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.1, B.1.617.2, B.1.618 (all of which were first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titres against the variant viruses-particularly the B.1.617.1 variant-seemed to be lower than the titre against the USA-WA1/2020 virus, but all sera tested neutralized the variant viruses at titres of at least 1:40. The susceptibility of the variant strains to neutralization elicited by the BNT162b2 vaccine supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic globally.

Authors+Show Affiliations

Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA.Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA.Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA. Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA. Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA. Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA.Pfizer Vaccine Research and Development, Pearl River, NY, USA.Pfizer Vaccine Research and Development, Pearl River, NY, USA.Pfizer Vaccine Research and Development, Pearl River, NY, USA.Pfizer Vaccine Research and Development, Pearl River, NY, USA.BioNTech, Mainz, Germany.Pfizer Vaccine Research and Development, Pearl River, NY, USA.BioNTech, Mainz, Germany. ugur.sahin@biontech.de.Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA. xuxie@utmb.edu.Pfizer Vaccine Research and Development, Pearl River, NY, USA. philip.dormitzer@pfizer.com.Institute for Human Infections and Immunity, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. Center for Biodefense and Emerging Infectious Diseases, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu. Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX, USA. peshi@utmb.edu.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

34111888

Citation

Liu, Jianying, et al. "BNT162b2-elicited Neutralization of B.1.617 and Other SARS-CoV-2 Variants." Nature, vol. 596, no. 7871, 2021, pp. 273-275.
Liu J, Liu Y, Xia H, et al. BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature. 2021;596(7871):273-275.
Liu, J., Liu, Y., Xia, H., Zou, J., Weaver, S. C., Swanson, K. A., Cai, H., Cutler, M., Cooper, D., Muik, A., Jansen, K. U., Sahin, U., Xie, X., Dormitzer, P. R., & Shi, P. Y. (2021). BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. Nature, 596(7871), 273-275. https://doi.org/10.1038/s41586-021-03693-y
Liu J, et al. BNT162b2-elicited Neutralization of B.1.617 and Other SARS-CoV-2 Variants. Nature. 2021;596(7871):273-275. PubMed PMID: 34111888.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. AU - Liu,Jianying, AU - Liu,Yang, AU - Xia,Hongjie, AU - Zou,Jing, AU - Weaver,Scott C, AU - Swanson,Kena A, AU - Cai,Hui, AU - Cutler,Mark, AU - Cooper,David, AU - Muik,Alexander, AU - Jansen,Kathrin U, AU - Sahin,Ugur, AU - Xie,Xuping, AU - Dormitzer,Philip R, AU - Shi,Pei-Yong, Y1 - 2021/06/10/ PY - 2021/05/19/received PY - 2021/06/04/accepted PY - 2021/6/11/pubmed PY - 2021/8/20/medline PY - 2021/6/10/entrez SP - 273 EP - 275 JF - Nature JO - Nature VL - 596 IS - 7871 N2 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is continuing to evolve around the world, generating new variants that are of concern on the basis of their potential for altered transmissibility, pathogenicity, and coverage by vaccines and therapeutic agents1-5. Here we show that serum samples taken from twenty human volunteers, two or four weeks after their second dose of the BNT162b2 vaccine, neutralize engineered SARS-CoV-2 with a USA-WA1/2020 genetic background (a virus strain isolated in January 2020) and spike glycoproteins from the recently identified B.1.617.1, B.1.617.2, B.1.618 (all of which were first identified in India) or B.1.525 (first identified in Nigeria) lineages. Geometric mean plaque reduction neutralization titres against the variant viruses-particularly the B.1.617.1 variant-seemed to be lower than the titre against the USA-WA1/2020 virus, but all sera tested neutralized the variant viruses at titres of at least 1:40. The susceptibility of the variant strains to neutralization elicited by the BNT162b2 vaccine supports mass immunization as a central strategy to end the coronavirus disease 2019 (COVID-19) pandemic globally. SN - 1476-4687 UR - https://www.unboundmedicine.com/medline/citation/34111888/BNT162b2_elicited_neutralization_of_B_1_617_and_other_SARS_CoV_2_variants_ L2 - https://doi.org/10.1038/s41586-021-03693-y DB - PRIME DP - Unbound Medicine ER -